The global Acute Myeloid Leukemia (AML) therapeutics market is projected to grow from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, registering a compound annual growth rate (CAGR) of 9.2% between 2026 and 2036, according to a new report by Fact.MR. The market is expected to create an absolute dollar opportunity of approximately USD 5.9 billion, expanding nearly 2.4 times its value over the forecast period. The growth trajectory reflects the increasing shift toward genomics-driven treatment strategies, targeted therapies, and personalized medicine approaches that are transforming the management of acute myeloid leukemia worldwide.
As healthcare providers increasingly adopt molecular diagnostics and mutation-based treatment selection, AML therapeutics are evolving from traditional chemotherapy-focused regimens toward highly individualized treatment pathways designed to improve patient outcomes and reduce disease recurrence. Targeted therapies are expected to account for 36% of market share in 2026, making them the largest drug class segment within the AML therapeutics market. The increasing availability of mutation-specific drugs and novel targeted agents is expanding treatment options for patients with genetically defined AML subtypes, offering enhanced efficacy and improved tolerability compared to conventional treatment approaches.
By disease type, newly diagnosed AML is projected to hold 48% market share in 2026, as initial treatment regimens generate the highest therapy volumes. Hospitals remain the leading end-user segment, accounting for 55% of market demand, due to the intensive inpatient management required for AML treatment. Similarly, hospital pharmacies maintain a dominant position with 49% market share due to the complexity of AML therapies and the need for specialized handling and administration protocols.
One of the strongest growth drivers for the market is the increasing availability of therapies for relapsed and refractory AML patients. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients who previously had limited treatment alternatives. Recent regulatory approvals and clinical advancements continue to strengthen the treatment landscape, offering new hope for patients with difficult-to-treat forms of AML.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR: 'Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations.'
Regional markets display strong growth potential, with South Asia and East Asia emerging as high-growth regions due to expanding cancer care infrastructure and increasing access to molecular diagnostics. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending. Among key countries, India is projected to grow at 11.8% CAGR, China at 10.9% CAGR, and the United States at 8.7% CAGR. A sample report with detailed forecasts and strategic recommendations is available at Fact.MR sample page.
Key companies operating in the market include AbbVie Inc., Genentech/Roche, Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. Industry participants are investing heavily in precision medicine, molecular diagnostics partnerships, clinical trials, and patient access programs to strengthen their competitive positioning. The full report is available at Fact.MR report page.
The future of the AML therapeutics market will be shaped by continued advances in precision oncology, molecular diagnostics, targeted therapies, and lower-intensity treatment regimens. As mutation testing becomes increasingly integrated into routine clinical practice, treatment decisions will become more personalized and data-driven. The growing availability of oral targeted therapies, relapse-focused drugs, and next-generation immuno-oncology approaches is expected to further expand treatment opportunities and improve patient outcomes.
